Dermatological Manifestations of COVID-19 in Patients Reporting to a Tertiary Care Hospital in Rawalpindi, Pakistan

Anjum Muhammad 1, Nadia Iftikhar 1, Asher Mashhood 1, Gurnam Virdi 2, Hafeez Ud Din 3, Afnan Akbar 4, Bilal Ahmad 5, Abrar Khalid 1

1. Dermatology, Pak-Emirates Military Hospital, Rawalpindi, PAK 2. Dermatology, Academy of Aesthetic Medicine, Sheffield, GBR 3. Histopathology, Armed Forces Institute of Pathology, Rawalpindi, PAK 4. Basic Sciences, Army Medical College, Rawalpindi, PAK 5. Endocrinology and Diabetes, Pak-Emirates Military Hospital, Rawalpindi, PAK

Corresponding author: Anjum Muhammad, anjumhassan87@gmail.com

Abstract

Introduction

The clinicopathological description of dermatological manifestations of COVID-19 leaves much to be desired. There is a need to determine their association with disease severity, outcome, and other clinical variables.

Objectives

The objectives of this study are to record and histopathologically examine the cutaneous manifestations of COVID-19 and correlate these to age, disease severity, and mortality.

Methods

All confirmed COVID-19 patients admitted to a single tertiary healthcare hospital in Rawalpindi, Pakistan, were included. Their diseases were classified as mild, moderate, severe, and critical. The recent onset skin eruptions in these patients were recorded via photographs along with relevant clinical data. The photographs were independently reviewed by a group of three dermatologists without knowledge of the clinical information. The skin manifestations were divided into disease-specific and nonspecific categories using an already defined algorithm. Histopathological examination of skin manifestations was conducted.

Results

A total of 23% (n=47) had "new" skin manifestations. Specific skin findings were seen in 21.6% (n=44), which consisted of ecchymosis/purpura in 50% (n=22), maculopapular exanthem in 18% (n=8), livedo reticularis in 16.2% (n=7), ischemia/gangrene in 16.2% (n=7), perniosis in 15.9% (n=7), vesiculo-bullous rash in 9% (n=4) and urticaria in 4% (n=1). Non-specific findings were seen in 6% (n=13) and included bedsores, dermatitis passivata, dryness, herpes labialis, oral ulcerations, and nasogastric tube-induced ulcerations. There was a significant association (p=0.03) between disease severity and specific skin lesions. Ischemia/gangrene was significantly associated with COVID-19 disease severity and mortality. Vesiculobullous lesions were associated with higher mortality, though not with disease severity. Livedo reticularis had a higher-than-expected count in critical disease, albeit statistically insignificant. The association of maculopapular exanthem and ecchymosis/purpura with severe/critical disease was statistically insignificant. Urticaria was significantly associated with low disease severity. Mean age with specific manifestations was 56.86 ± 15.81 and with nonspecific/without any manifestations was 42.58 ± 16.96, a highly significant difference, with p-value < 0.001. Old age (>60 years) was significantly associated with ecchymosis (p=0.038), maculopapular exanthem (p=0.021), and vesiculo-bullous rash (p=0.029). Histopathology varied according to the type of skin lesion.

Conclusions

Dermatological manifestations coexist in many patients and tend to appear more in severe cases of COVID-19 among the older age group and only minimally in mild/moderate cases. Their presence could help set prognostic criteria of COVID-19 disease in the future.

Categories: Dermatology, Pathology, Infectious Disease

Keywords: covid 19, dermatological manifestation, limb ischemia, covid and skin, histological features

Introduction

COVID-19 was first detected in the Chinese city of Wuhan in December 2019 as pneumonia that involved multiple organ systems [1]. The newfound virus would promptly spread across swathes of the planet and be...
declared a global pandemic shortly after.

As part of the multisystem involvement that COVID-19 encompasses [2], the skin can exhibit various manifestations. Descriptions of the cutaneous manifestations of COVID-19 have been attempted by various studies across the globe showing fluctuating frequency, types, extent, and association to the disease severity. The frequency of dermatological manifestations may vary from 0.2% to 20.4% [2-5]. These include maculopapular exanthem, urticarial, vesicular/bullous, perniosis ecchymosis/purpura, livedo reticularis, acral ischemia/gangrene, and maculopapular rash with exanthem. COVID-19 may also cause non-specific dermatological manifestations that result from various treatment sequelae, prolonged in-hospital care, and poor skin hygiene of patients [6,7] while being isolated for extended durations.

The limitations of these studies were variable; some were individual case studies, while others had small sample sizes [8,9] or lacked adequate pictorial data [10] due to safety concerns related to the highly contagious virus [3]. Even fewer studies performed the histological examination of the lesions.

Our study attempts to corroborate the previously detailed classifications and descriptions of the cutaneous manifestations of COVID-19, describes their histological features, and attempts to relate them with age, disease severity, and mortality.

**Materials And Methods**

All confirmed COVID-19 patients (with laboratory confirmation of SARS-CoV-2, irrespective of the severity of their clinical signs and symptoms) admitted in a tertiary inpatient health care facility in Rawalpindi, Pakistan were included. All patients who showed recent-onset skin eruptions were included. Their diseases were classified as mild, moderate, severe, and critical as per WHO guidelines [11].

This descriptive study was conducted in July 2020 for a duration of one month. A specially designed form was used for data collection and pictures were taken of all the skin manifestations using full personal protective equipment protocol.

The photographs were independently reviewed by a group of three dermatologists without knowledge of the clinical information. The skin lesions were then classified using an algorithm for the classification of cutaneous manifestations of COVID-19 [12]. Analysis of descriptive data and distribution tests was done using SPSS Statistics 23 (IBM Corp., Armonk, NY).

The study was approved by an ethical committee (A/28/180/EC/2020). All patients, or their next of kin in case of minors/critically ill, gave their informed consent to participate and explicit consent to use their pictures in publications and perform biopsies when needed.

Complete blood picture including eosinophilic counts was performed to rule out the possible association of the skin manifestations with the drugs administered during the treatment. Histopathological analysis was carried out on biopsies.

**Results**

We observed 204 cases during the peak of the epidemic in Pakistan. The patients' ages ranged from 13 years to 93 years. The median age was 45.5 years. Patients above 60 years of age constituted 27% (n=55) of the sample. The rest 73% (n=149) were below 60 years. Males accounted for 88.2% (n=180), while female, 11.8% (n=24) of cases. Case fatality was 4.4% (n=9). Around 92% (n=188) were discharged on recovery and 3.4% (n=7) patients remained under treatment till the compilation of this data. Also, of the COVID-19 patients, 60% (n=114) had mild, 18% (n=38) had moderate, and 17.6% (n=36) had severe, while 7.8% (n=16) was critical according to their clinical and laboratory findings. No deaths were reported in mild and moderate disease, while 2.6% (n=1) patients died in severe and 50% (n=8) died in the critical disease category. Around 29% (n=60) of our patients were comorbid, the most frequent being diabetes (15.4%, n=27), hypertension (18.3%, n=37), ischemic heart disease (11.2%, n=23) and COPD/asthma (4.5%, n=9). Combinations of two or more comorbidities were seen in 13.2% (n=27).

Image review and data analysis, lead to the description of two major clinical classes i.e. specific and nonspecific skin findings. The specific findings included seven major clinical patterns namely vesiculobullous, digital ischemia/gangrene, maculopapular exanthem, and livedo reticularis (Figures 1-4). Additional findings included ecchymosis/purpura, perniosis, and urticarial manifestations. Non-specific skin manifestations included bedsores, dermatitis passivata, dryness, herpes labialis, oral ulcerations, and nasogastric tube-induced ulcerations.
FIGURE 1: Bullous rash on the lateral malleolus of a critically ill young male.
FIGURE 2: Vesiculobullous rash with ischemia on the lower limb of a critically ill middle-aged male.
FIGURE 3: Digital ischemia and perniosis in a critically ill middle-aged female.
Around 23% (n=47) had some or other “new” skin manifestations during the course of their infection: these were skin manifestations that appeared on the patients’ skin within the incubation period following contact with an infected person or following the development of other signs and symptoms of COVID-19. The onset of skin lesions ranged from five days prior to COVID-19 diagnosis to 26 days after diagnosis. Only one patient (2.2%) reported palmar livedo reticularis five days prior to diagnosis. Lesions appeared in the first, second and third week of illness in 27.2% (n=12), 36.3% (n=16), and 34% (n=15) of the patients respectively. Specific skin findings were seen in 21.6% (n=44). Amongst these, 16.7% (n=34) patients had specific manifestations only, while 1.5% (n=3) had nonspecific skin manifestations only. A combination of both was seen in 4.9% (n=10). No skin findings were seen in 77% (n=157) of patients. The summary of specific dermatological manifestations and their histopathology is shown here (Table 1).
| Age | Sex | Severity of Disease | Comorbidities | Onset of Rash | Type of Skin Rash | Biopsy Findings | Disease Outcome |
|-----|-----|---------------------|---------------|--------------|------------------|----------------|----------------|
| 92  | M   | Critical            | HTN           | 09           | Ecchymosis/purpura | -              | Discharged     |
| 40  | M   | Severe              | Nil           | 08           | Perniosis, ecchymosis | -              | Discharged     |
| 67  | F   | Severe              | DM, HTN       | 07           | Maculopapular/exanthem | Orbiokeratosis, thin necrotic epithelium stripped from dermis, perivascular lymphocytic infiltration in dermis with mucinous degeneration. | Under treatment |
| 60  | M   | Critical            | Nil           | 09           | Perniosis + livedo reticularis + ischemia | -              | Under treatment |
| 60  | M   | Severe              | DM, IHD       | 17           | Maculopapular/exanthem | Lymphocytic perivascular infiltration in dermis. | Under treatment |
| 48  | M   | Critical            | Nil           | 04           | Livedo reticularis | -              | Under treatment |
| 27  | M   | Critical            | HIV           | 02           | Vesicular/bullous | Hyperkeratosis, necrotic epidermis, sub-epidermal blister, perivascular lymphocytic infiltration in dermis; SJS/TEN-like picture. | Death |
| 73  | M   | Critical            | DM, HTN, IHD  | 10           | Maculopapular/exanthem | Chronic inflammatory lymphocytic infiltration in dermis; necrotic areas in epidermis. | Under treatment |
| 61  | M   | Critical            | DM, HTN, IHD, COPD | 05    | Livedo reticularis | Perivascular lymphocytic infiltration in dermis. | Under treatment |
| 72  | M   | Severe              | DM, HTN, IHD  | 20           | Perniosis | -              | Discharged     |
| 60  | F   | Mild                | Nil           | 08           | Ecchymosis/purpura | -              | Under treatment |
| 55  | M   | Critical            | DM            | 17           | Perniosis + ischemia | -              | Death          |
| 72  | M   | Critical            | DM, HTN       | 07           | Ecchymosis + ischemia + blister | -              | Death          |
| 59  | M   | Severe              | Asthma        | 10           | Ecchymosis/purpura | -              | Discharged     |
| 80  | M   | Severe              | DM, HTN, IHD, COPD | 16    | Ecchymosis/purpura | -              | Death          |
| 39  | M   | Severe              | Nil           | 19           | Ecchymosis/purpura | -              | Discharged     |
| 55  | M   | Severe              | DM, HTN, IHD  | 12           | Ecchymosis/purpura | -              | Discharged     |
| 70  | M   | Severe              | Nil           | 18           | Ecchymosis/purpura | -              | Discharged     |
| 59  | M   | Severe              | Nil           | 18           | Ecchymosis/purpura | -              | Discharged     |
| 77  | F   | Critical            | DM, HTN, IHD  | 5            | Ecchymosis/purpura | -              | Death          |
| 31  | M   | Mild                | IHD           | 12           | Urticarial like rash | -              | Discharged     |
| 48  | F   | Moderate            | Nil           | 11           | Ecchymosis/purpura | -              | Discharged     |
| 26  | M   | Moderate            | Nil           | 3            | Ecchymosis/purpura | -              | Discharged     |
| 65  | M   | Severe              | HTN           | 12           | Ecchymosis/purpura | -              | Discharged     |
| 62  | F   | Severe              | DM, HTN, IHD, COPD | 16    | Ecchymosis/purpura | -              | Discharged     |
| 54  | M   | Mild                | Nil           | 11           | Ecchymosis/purpura | -              | Discharged     |
| 40  | M   | Mild                | Lymphoma      | 10           | Livedo reticularis | Hyperkeratosis, hypergranulosis, moderate epidermal hyperplasia with perivascular lymphocytic infiltration in dermis. | Discharged     |
| 48  | M   | Moderate            | HCV/DCLD      | 08           | Maculopapular/exanthem | -              | Discharged     |
| #  | Gender | Age | Severity | Disease | Skin manifestation | Biopsy findings                                                                 | Outcome |
|----|--------|-----|----------|---------|-------------------|--------------------------------------------------------------------------------|---------|
| 52 | M      | 52  | Severe   | Bipolar/depression | Maculopapular/exanthem | Orthokeratosis, thin epidermis, loss of rete ridges, and perivascular lymphocytic infiltration with RBC extravasation in dermis. | Discharged |
| 43 | M      | 43  | Moderate | Nil     | Ecchymosis/purpura | - | Discharged |
| 40 | M      | 40  | Severe   | Lymphoma | -5 | Livedo reticularis | Mild perivascular lymphocytic infiltration in the upper dermis; acanthosis, hyperkeratosis. | Discharged |
| 36 | M      | 36  | Severe   | Nil     | 26 | Ecchymosis/purpura | - | Discharged |
| 65 | F      | 65  | Moderate | CA gallbladder | 06 | Maculopapular/exanthem | Hyper and orthokeratosis, increased basal and suprabasal pigmentation; perivascular lymphocytic infiltration in dermis. | Discharged |
| 62 | M      | 62  | Severe   | Nil     | 22 | Vesicular/bullous | - | Discharged |
| 59 | M      | 59  | Moderate | HTN     | 10 | Ecchymosis/purpura | - | Discharged |
| 40 | F      | 40  | Critical | DM      | 08 | Perniosis + livedo; reticularis + ischemia | Occasional perivascular lymphocytic infiltration, orthokeratosis, and epidermal thinning. | Death |
| 43 | M      | 43  | Moderate | Nil     | 10 | Maculopapular/exanthem | - | Discharged |
| 85 | M      | 85  | Critical | DM, IHD | 06 | Ecchymosis/purpura | - | Discharged |
| 72 | M      | 72  | Critical | Nil     | 19 | Ecchymosis + ischemia + blister | - | Death |
| 55 | M      | 55  | Severe   | Nil     | 13 | Ecchymosis/purpura | - | Discharged |
| 70 | M      | 70  | Moderate | Nil     | 05 | Maculopapular/exanthem | - | Discharged |
| 72 | M      | 72  | Critical | DM, HTN | 14 | Ischemic gangrene | Mild acanthosis increased basal pigmentation and vacuolated keratinocytes; dermal edema, congested blood vessels, extensive RBC extravasation throughout the dermis. | Death |
| 52 | F      | 52  | Critical | Obesity, DM | 07 | Vesicular/bullous | Focal areas of epidermal necrosis attached to the underlying dermis, which, had acute on chronic inflammatory infiltration. | Death |

**TABLE 1: Descriptive characteristics of the patients with specific skin manifestations along with biopsy findings.**

DM: diabetes mellitus; HTN: hypertension; IHD: ischemic heart disease; SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis; COPD: chronic obstructive pulmonary disease; HIV: human immunodeficiency virus, HCV/DCLD: Hepatitis C virus/decompensated liver disease

Amongst patients with specific skin findings, ecchymosis/purpura was observed in a total of 50% (n=22), either in combination with ischemia and blister (4.5%, n=2) or in isolation in 45.4% (n=20). Of the total 22 patients with ecchymosis/purpura, 63% (n=14) received enoxaparin injections while 36% (n=8) did not. Mild or moderate thrombocytopenia (< 150×10⁶/ml - ≥ 50 × 10⁶/ml) was seen in 59% (n=13) of patients with ecchymosis/purpura. Thrombocytopenia, without enoxaparin, was noted in 22.7% (n=5/22), while thrombocytopenia with enoxaparin was seen in 31.8% (n=7/22) of ecchymosis/purpura patients. Similarly, 27.2% (n=6/22) received enoxaparin but had no thrombocytopenia, while 13.6% (n=3/22) of ecchymosis/purpura patients had neither enoxaparin nor thrombocytopenia. Maculopapular (exanthem) rash was seen in 18% (n=8). Livedo reticularis involving acral areas was present in 16.2% (n=7) patients, either alone (9.2%, n=4) or in combination with perniosis and ischemic changes, in 6.9% (n=3). Perniosis was found in 15.9% (n=7) in total, either alone (4.5%, n=2) or in combination with ischemia (4.5%, n=2 each) or livedo reticularis and ischemia (6.8%, n=3). Ischemic/gangrenous changes were seen in 16.2% (n=7) in
total, either in combination with perniosis (11.3%, n=5), livedo reticularis (6.8%, n=3) or ecchymosis (4.5%, n=2). Vesiculo-bullous/blistering lesions were observed in isolation 4.6% (n=2) or in combination with ischemic changes in 4.6% (n=2), while 9.2% (n=4) in totality. Lastly, Urticarial lesions were seen in one patient (4.6%).

Amongst 13 patients who manifested nonspecific findings, herpes labialis constituted 23% (n=3), while bedsores, dermatitis passivata, and xerosis constituted 15.3% (n=2) of the lesions. Nasogastric tube-induced ulcerations, oral ulcerations, eczema, and vitiligo were seen in one patient each.

Our study found a significant association (p=0.03) between COVID-19 disease severity and the prevalence of specific skin lesions. Amongst patients with specific findings, only 9% (n=4) had mild cases of COVID-19. On the contrary, the disease severity was moderate in 20.4% (n=9), severe in 38.6% (n=17), and critical in 31.8% (n=14) (Table 2).

### TABLE 2: Relation of specific skin manifestation with severity of COVID-19 disease.

| Disease             | Presence | Mild | Moderate | Severe | Critical | Total | p-value | Cramers V value |
|---------------------|----------|------|----------|--------|----------|-------|---------|-----------------|
| Ischemia/gangrene   | No       | 4    | 9        | 16     | 8        | 37    | 0.010*  | 0.508           |
|                     | Yes      | 0    | 0        | 1      | 6        | 7     |         |                 |
| Livedo Reticularis  | No       | 3    | 9        | 16     | 9        | 37    | 0.062   |                 |
|                     | Yes      | 1    | 0        | 1      | 5        | 7     |         |                 |
| Ecchymosis          | No       | 2    | 4        | 7      | 9        | 22    | 0.619   |                 |
|                     | Yes      | 1    | 0        | 1      | 5        | 22    |         |                 |
| Perniosis           | No       | 4    | 9        | 14     | 10       | 37    | 0.243   |                 |
|                     | Yes      | 0    | 0        | 3      | 4        | 7     |         |                 |
| Maculopapular rash  | No       | 4    | 5        | 14     | 13       | 36    | 0.102   |                 |
|                     | Yes      | 0    | 4        | 3      | 1        | 8     |         |                 |
| Urticaria           | No       | 3    | 9        | 17     | 14       | 43    | 0.017*  | 0.482           |
|                     | Yes      | 1    | 0        | 0      | 0        | 1     |         |                 |
| Vesiculobullous     | No       | 4    | 9        | 16     | 11       | 40    | 0.252   |                 |
|                     | Yes      | 0    | 0        | 1      | 3        | 4     |         |                 |

Significance level < 0.05, Cramers V value given for significant outcomes. Outcomes with adjusted residual > 1.96 are shown in bold.

Ischemia/gangrene was significantly associated with disease severity (p=0.010, Cramér’s V=0.550, adjusted residual=3.3) and mortality (p<0.001, Cramér’s V=0.550). More than 50% (n=5) of deaths occurred in patients with such lesions (Table 3).
| Disease                | Presence | Outcome | Total | p-value  | Cramér's V |
|-----------------------|----------|---------|-------|----------|------------|
|                       |          |         |       |          |            |
|                       |          | Discharge | Death |          |            |
| Ischemia/gangrene     | No       | 33       | 4     | 37       | <0.001*    | 0.550      |
|                       | Yes      | 2        | 5     | 7        |            |            |
|                       |          |          |       |          |            |
| Livedo reticularis    | No       | 30       | 7     | 37       | 0.562      |            |
|                       | Yes      | 5        | 2     | 7        |            |            |
|                       |          |          |       |          |            |
| Ecchymosis            | No       | 17       | 5     | 22       | 0.709      |            |
|                       | Yes      | 18       | 4     | 22       |            |            |
|                       |          |          |       |          |            |
| Perniosis             | No       | 31       | 6     | 37       | 0.109      |            |
|                       | Yes      | 4        | 3     | 7        |            |            |
|                       |          |          |       |          |            |
| Maculopapular rash    | No       | 27       | 9     | 36       | 0.113      |            |
|                       | Yes      | 8        | 0     | 8        |            |            |
|                       |          |          |       |          |            |
| Urticaria             | No       | 34       | 9     | 43       | 0.608      |            |
|                       | Yes      | 1        | 0     | 1        |            |            |
|                       |          |          |       |          |            |
| Vesiculobullous       | No       | 34       | 6     | 40       | 0.005*     | 0.428      |
|                       | Yes      | 1        | 3     | 4        |            |            |

TABLE 3: Relation of specific skin manifestation with outcome of COVID-19 disease.
Significance level < 0.05, Cramér’s V given for significant outcomes

Livedo reticularis had a higher than the expected count in the critical disease category (adjusted residual=2.5), though the association was not statistically significant (p=0.062). Vesiculobullous lesions were associated with higher mortality (n=3/9, p=0.005, Cramér’s V=0.428) (Table 3).

Around 50% (n=4) of maculopapular exanthem and 65% (n=13) of ecchymosis/purpura were seen in severe or critical cases. However, the statistical analyses of both these lesions were non-significant in relation to disease severity and mortality. Urticaria was significantly associated with low disease severity (Table 2).

The mean age of patients with specific skin manifestations was 56.86 ± 15.81, while that of patients either with nonspecific/without any skin manifestations was 42.58 ± 16.96. This difference is highly significant, with a p-value < 0.001 (independent samples t-test). Analysis of age against individual specific skin manifestation shows that old age (>60 years) is significantly associated with ecchymosis (p=0.038), maculopapular exanthem (p=0.021), and vesiculobullous rash (p=0.029). Age showed no association with ischemia/necrosis, livedo reticularis, perniosis or urticaria (p=0.067, 0.992, 0.335, and 0.542, respectively) (Table 4).
| Age Group | Ischemia | Livedo reticularis | Purpura/Eccymosis | Perniosis | Maculo-papular rash | Urticaria | Vesiculo bullous rash |
|-----------|----------|-------------------|-------------------|-----------|--------------------|-----------|----------------------|
| Young (N=149) | 146 | 3 | 144 | 5 | 137 | 12 | 145 | 4 | 146 | 3 | 148 | 1 | 148 | 1 |
| Old (N=55) | 51 | 4 | 53 | 2 | 45 | 10 | 52 | 3 | 50 | 5 | 55 | 0 | 52 | 3 |
| p-value | 0.067 | 0.992 | **0.038** | 0.335 | **0.021** | 0.542 | **0.029** |

**TABLE 4: Age distribution of sample in relation to specific skin manifestation**

Significant p-values are marked in bold.

Histopathological examination of livedo reticularis, in one sample, showed fibrinoid necrosis, vascular congestion, extravasation of RBCs and mild perivascular lymphocytic infiltration in the papillary dermis, consistent with lymphocytic vasculitis, while the lower dermis was unremarkable (Figure 5). Five samples exhibited hyperkeratosis, hypergranulosis and perivascular lymphocytic infiltration in the upper dermis. Biopsy couldn't be performed in one case.
FIGURE 5: Biopsy of livedo reticularis on foot, showing some of the blood vessels with fibrinoid necrosis, congestions with extravasation of RBCs and mild perivascular lymphocytic infiltration in papillary dermis, consistent with lymphocytic vasculitis. H&E stain, 10x magnification.

Five samples exhibited hyperkeratosis, hypergranulosis, and perivascular lymphocytic infiltration in the upper dermis. Biopsy couldn’t be performed in one case. In the case of maculopapular rash, one biopsy manifested orthokeratosis and the dermis had perivascular lymphocytic infiltration with collagen fibers separated by mucinous material (mucinous degeneration of dermis). In another sample, orthokeratosis, thinning of the epidermis with loss of rete ridges along with perivascular lymphocytic infiltration with RBC extravasation in the dermis, was seen (Figure 6).
FIGURE 6: Biopsy of maculopapular rash on the forearm, showing orthokeratosis, thinning of epidermis with loss of rete ridges along with perivascular lymphocytic infiltration with RBCs extravasation in dermis. H&E stain, 10x magnification

Three samples showed mild perivascular lymphocytic infiltration in the dermis. Biopsies couldn’t be performed in the rest of the three cases. In a sample of necrotic plaque, the epidermis showed follicular plugging, mild acanthosis, increased basal pigmentation and vacuolated keratinocytes. There was dermal edema with congested blood vessels and extensive RBC extravasation throughout the dermis. The biopsy of bullous/blister tissue from one patient manifested hyperkeratosis with the underlying necrotic epidermis separated from dermis via a sub-epidermal blister. The dermis revealed perivascular lymphocytic infiltration (Figure 7).
FIGURE 7: Biopsy of bullous/blister tissue from patient shown in Figure 1, showing hyperkeratosis with underlying necrotic epidermis, separated from dermis via a sub-epidermal blister. The dermis showed perivascular lymphocytic infiltration. H&E stain, 10x magnification.

Another sample of tense blisters on the face and limbs showed focal areas of epidermal necrosis attached to the underlying dermis, which in turn had acute on chronic inflammatory infiltration (Figure 8).
Histopathological examination was not done for ecchymosis/purpura, perniosis, urticaria and nonspecific skin manifestations.

Discussion

Our study chronicles several cutaneous patterns associated with COVID-19, indicating that a considerably large group of patients may have dermatological manifestations, appearing at different instances in the course of the disease at varying levels of severity, likely contributing to defining the prognosis of the disease. The description of certain histological patterns in our study may further enhance our knowledge about these manifestations. With a large number and distribution of participants, all of them testing positive for COVID-19, our sample is truly representative of the distribution of cutaneous lesions in COVID-19. Our attempt to describe the skin lesions in patients with mild to critical disease, as well as exclusion of suspected patients and testing for other respiratory viruses, reduced the chances of a bias in the results further. It is possible that some of the specific findings may have causes other than COVID-19, an example being clexane-induced ecchymosis. We tried to rule out those via carefully tracking history and examinations where an alternate cause could be suspected. Drug-induced rashes were ruled out by tracking history, careful analysis of the cutaneous findings, and performing peripheral eosinophil counts as well biopsies where feasible.

The majority of the cutaneous manifestations we observed appeared late in the course of the disease. One of the possible mechanisms behind this could be a delayed immune-mediated reaction to the virus in genetically predisposed individuals [13, 14].

Ecchymosis/purpura in the majority of patients appeared late in the disease course (second week or beyond) making it an unusable clinical feature in early diagnosis of COVID-19. We found a significant association of these lesions with a higher age group, not reported by earlier studies, to the best of our knowledge. Though statistically insignificant, two-thirds of these lesions were seen exclusively in severe/critical cases. Unlike a Turkish study [15] we noted a possible connection of ecchymosis/purpura with COVID-19 induced thrombocytopenia in 22.7% (n=5/22) patients, who had thrombocytopenia without clexane administration. Thrombocytopenia itself may be associated with a high risk of severe COVID-19 disease and mortality [16] thus serving as a clinical indicator of worsening disease during hospitalization. Other unexplained mechanisms involving vascular damage possibly via immune dysregulation, vasculitis, or thrombosis [17, 18].
could be implied in 13.6% (n=3/22) of ecchymoses/purpura patients, who neither had thrombocytopenia nor clexane.

Maculopapular lesions tend to concur with other symptoms appearing in the first or the second week of illness. We found a statistically significant association of old age (>60 years) with the presence of a maculopapular rash. This was consistent with a systemic review [19] which noted the mean age of patients with maculopapular rash to be 60.4 years. In contrast to a Spanish study [20], we didn’t find these lesions to be either exclusive to severe/critical disease or associated with any mortality in our sample. Histopathological features of maculopapular lesions in our study are somewhat consistent with descriptions provided by earlier case reports of such lesions [21, 22].

Contrary to others [13], we found a higher incidence of livedo reticularis in our COVID-19 disease sample. The rash appeared in the first week of illness in most cases. Consistent with a Spanish study [20], mostly elderly patients manifested such findings in our sample. A higher than expected number of livedo reticularis patients presented with severe/critical COVID-19 disease. Although statistical significance was not found, further research is warranted to ascertain the above-mentioned relationship. Livedo reticularis may either be the primary manifestations of the disease or may point towards complications leading to vascular occlusion, as COVID-19 has already been linked to coagulation anomalies and vascular damage [23]. The presence of fibrinoid necrosis in papillary dermal vessels with congestion, RBC extravasation, and mild perivascular lymphocytic infiltration in a biopsy of livedo reticularis in our study, further augments this treatise. Livedo reticularis also exhibited hyperkeratosis, epidermal hyperplasia, hypergranulosis, and perivascular lymphocytic infiltration with RBC extravasation in the upper dermis in five biopsy specimens. A systemic study that compiled a histological description of livedo reticularis rash by Li et al. [13] reported similar histological findings. Livedo reticularis may help raise suspicion of COVID-19 as it appears earlier in the disease course, thus helpful in its diagnosis, albeit in a minority.

Pseudo-chilblain appears like perniosis. Considering that they customarily appear in July’s warm weather, with the average high temperature being 35.7°C [24], a noteworthy increased incidence as perceived by dermatologists, all patients being COVID-19 positive and with no previous history of such lesions, a COVID-19 link becomes highly plausible. The findings are consistent with other studies that reported perniosis-like lesions in 318 cases from eight countries [25], negating some earlier assumptions that considered these lesions to be induced by cold temperature and immobility [8]. Pseudo-chilblains appeared later, either alone or in combination with ischemic/blistering lesions in our sample. Consistent with a Spanish study [20], their association with disease severity was statistically insignificant.

Ischemic/gangrenous lesions appeared late in the disease course, involving fingers, digits, and even whole limbs (n=2) or forearm skin (n=2) in some cases. Unlike previous studies [20], we think that these dry gangrenes could appear at any age and are particularly high in severe/critical cases. Our research correlates these findings with a bad prognosis and high mortality as reported by other limited-scale observations [26]. The presence of ischemia/gangrene in COVID-19 disease considerably augments the concept of a synergy between vasculitis and hypercoagulable states induced by COVID-19, as reported in earlier studies [8, 27].

Vesiculo bullous lesions might appear early or later in the disease course. They were significantly associated with higher mortality (n=5-9) in our cohort. We found no studies that correlated these lesions to COVID-19 mortality. Though statistically insignificant, we observed these to be far more frequent in severe/critically ill patients. Their incidence was far less compared to other skin manifestations in our study.

Consistent with a previous study [20], we think that urticarial lesions may be accredited to many causes. They do not predate other symptoms and hence, are unhelpful in making a diagnosis.

Apart from offering specific systemic therapy to treat COVID-19, clinicians and nursing staff should also give attention to maintaining general skin health and hygiene, to prevent and treat non-COVID-19 related skin issues such as dermatitis passivata, bedsores, xerosis, oral ulcers, and nasogastric tube induced ulcers [6, 7]. As observed in our study, a lot of patients, due to a lack of knowledge regarding this novel disease, didn’t know whether to follow the usual skincare routine and take showers or not. COVID-19 patients are especially prone to have neglected skin hygiene due to prolonged and isolated in-hospital stays where patient and care provider interaction is minimal due to the highly infectious nature of the virus.

COVID-19 appears to be an unusual viral infection, as it can exhibit several clinical patterns [5] of dermatological manifestations. Unlike a previous study [20], a lot of our observed skin patterns did coexist in many of our patients.

As a whole, it could be stated that dermatological manifestations have a tendency to frequent more in patients with a severe/explosive disease course. The minimal presence of skin manifestation in mild/moderate COVID-19 cases that we report is consistent with a study in patients residing in the Tibetan plateau, where the disease course was generally mild in almost all patients [28].

The uniform and direct involvement of dermatologists/residents in the triage, admission, care as well as the
search for skin manifestations at all times and levels in our study, may have translated into an accurate reporting of the incidence of these skin findings and their association with disease severity. Especially when a few previous attempts have either reported a highly skewed incidence of skin findings involving almost all the patients [29] or reported minimal involvement of skin where observation was done by non-dermatological staff [30], others simply lacked photographic and/or histologic data [3].

The description of clinicopathologic features augments our existing knowledge on some of the patterns and provides an insight into the histology of cutaneous findings associated with COVID-19. Further structured clinical, molecular, serological, and histopathological studies are required to ascertain and explain the dermatological manifestations and their possible utilization for better management of the patients with COVID-19.

Conclusions
The majority of dermatological manifestations of COVID-19 such as pemphigus, ischemia, livedo reticularis, and ecchymosis/purpura are more frequent in severe/explosive cases than other manifestations such as vesiculobullous, ecchymosis, and maculopapular exanthem in the older age group. Ischemic/gangrenous and vesiculobullous lesions herald a bad prognosis with high mortality. The presence of these dermatological manifestations could help set prognostic criteria in the future.

There is a possible connection of ecchymosis/purpura with COVID-19-induced thrombocytopenia. Histopathological features vary according to the skin lesions. They may be specific or nonspecific. Attention should be given to maintaining general skin health and hygiene in the prevention and treatment of non-COVID-19 related skin issues.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Ethical Committee Pak-Emirates Military Hospital Rawalpindi issued approval A/28/180/EC/2020. It is to certify that Dr Muhammad Anjum, FCPS-II trainee in Dermatology is submitting the research titled, 'Dermatological Manifestations of Covid-19 in Pak-Emirates Military Hospital Rawalpindi'. It has been scrutinized and found ethically sound as all ethical issues have been addressed in this study. Furthermore, there is no conflict of interest in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Phelan AL, Katz R, Gostin LO: The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020, 325:709-10. 10.1001/jama.2020.1097
2. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016/S0140-6736(20)30183-5
3. Recalcati S: Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020, 34:e212-3. 10.1111/jdv.16387
4. Freeman EE, McMahon DE, Fitzgerald ME, et al.: The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19. J Am Acad Dermatol. 2020, 83:509-10. 10.1001/jaad.2020.04.045
5. Freeman EE, McMahon DE, Lipoff JB, et al.: The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020, 83:1118-29. 10.1016/j.jaad.2020.06.1016
6. Li Y, Temkin-Greener H, Shang, Gai X: COVID-19 infections and deaths among Connecticut nursing home residents: facility correlates. J Am Geriatr Soc. 2020, 68:1899-906. 10.1111/jgs.16689
7. Zingarelli EM, Ghiglione M, Pesce M, Orejuela I, Scarrone S, Panizza R: Facial pressure ulcers in a COVID-19 50-year-old female intubated patient. Indian J Plast Surg. 2020, 53:144-6. 10.1055/s-0040-1710403
8. Almrantz A, Aldarajji W: Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East. Clin Exp Dermatol. 2020, 45:746-8. 10.1111/ced.13435
9. Qian SZ, Pan JY: COVID-19 with limb ischemic necrosis. J Cardiothorac Vasc Anesth. 2020, 34:2846-7. 10.1053/j.jvca.2020.05.063
10. Fernández-Nieto D, Ortega-Quijano D, Segurado-Miravalles G, Pindado-Ortega C, Prieto-Barrios M, Jiménez-Cauhe J: Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies. J Eur Acad Dermatol Venereol. 2020, 34:e252-4. 10.1111/jdv.16470
11. World Health Organization: Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization, 2020. https://apps.who.int/iris/handle/10665/332196.
12. Ortega-Quijano D, Jiménez-Cauhe J, Selda-Enríquez G, Fernandez-Guarino M, Fernandez-Nieto D: Algorithm for the classification of COVID-19 rashes. J Am Acad Dermatol. 2020, 83:e105-4. 10.1016/j.jaad.2020.05.034
13. Li H, Zhao Y, Zhou L, Hu J: Cutaneous, skin histopathological manifestations and relationship to COVID-19 infection patients. Dermatol Ther. 2020, 33:e14157. 10.1111/dth.14157

14. Piccolo V, Neri I, Filippeschi C, et al.: Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 65 patients. J Eur Acad Dermatol Venereol. 2020, 34:e291-3. 10.1111/jdv.16226

15. Akin O, Altunkalem BN, Altinkılık DD, Üzuncağmır TK, Türsen U, Kutlubay Z: Cutaneous manifestations in hospitalized patients diagnosed as COVID-19. Dermatol Ther. 2020, 33:e13896. 10.1111/dth.13896

16. Lippi G, Plebani M, Henry BM: Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020, 506:145-8. 10.1016/j.cca.2020.05.022

17. Colmenero I, Santonja C, Alonso-Riaño M, et al.: SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol. 2020, 183:729-37. 10.1111/bjd.19327

18. Magro C, Mulvey JJ, Berlin D, et al.: Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020, 220:1-15. 10.1016/j.trsl.2020.04.007

19. Rahimi H, Tehranchinia Z: A Comprehensive review of cutaneous manifestations associated with COVID-19. Biomed Res Int. 2020, 2020:1236520. 10.1155/2020/1236520

20. Galvín Casas C, Catalá A, Carretero Hernández G, et al.: Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020, 183:71-7. 10.1111/bjd.19163

21. Ahouach B, Harent S, Ullmer A, et al.: Cutaneous lesions in a patient with COVID-19: are they related?. Br J Dermatol. 2020, 183:e51. 10.1111/bjd.19168

22. Zengarini C, Orioli G, Cascavilla A, et al.: Histological pattern in COVID-19-induced viral rash. J Eur Acad Dermatol Venereol. 2020, 34:e453-4. 10.1111/jdv.16569

23. Zhang Y, Xiao M, Zhang S, et al.: Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020, 382:e38. 10.1056/NEJMc2007575

24. July weather forecast and climate, Rawalpindi, Pakistan. (2021). Accessed: October 10, 2021: https://www.weather-atlas.com/en/pakistan/rawalpindi-weather-july#climate_text_1. https://www.weather-pk.com/en/pak....

25. Freeman EE, McAlonan DE, Lipoff JB, et al.: Pernio-like skin lesions associated with COVID-19: A case series of 518 patients from 8 countries. J Am Acad Dermatol. 2020, 83:486-92. 10.1016/j.jaad.2020.05.109

26. Zhang Y, Cao W, Xiao M, et al.: Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia [Article in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2020, 41:E006. 10.3760/cma.j.issn.0253-2727.2020.0006

27. Del Giudice P, Boudoumi D, Le Guen B, et al.: Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a likely consequence of both vasculitis and coagulopathy. J Eur Acad Dermatol Venereol. 2020, 34:e679-80. 10.1111/jdv.16763

28. Lei Y: Clinical features of imported cases of coronavirus disease 2019 in Tibetan patients in the Plateau area [PREPRINT]. MedRxiv. 2020, 2020. 10.1101/2020.05.09.20033126

29. Mungmunpuntipantip R, Wiwanitkit V: COVID-19 and cutaneous manifestations. J Eur Acad Dermatol Venereol. 2020, 34:e246. 10.1111/jdv.16483

30. Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382:1708-20. 10.1056/NEJMoa2002052